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7-Valent  pneumococcal  conjugate  vaccine  (PCV7)  immunization  in  adulthood  can  inhibit  allergic  asthma
in  mouse  model.  The  aim of  this  study  is  to investigate  the effects  of infant  PCV7  immunization  on young
adulthood  CD4+T cell subsets  in  a murine  allergic  airway  disease  (AAD)  model.  Our study  indicated  that
infant  PCV7  immunization  can  inhibit  young  adulthood  airway  inﬂammation  and  airway  hyperrespon-
siveness  (AHR)  by  inducing  the  production  of  Foxp3+Treg,  Th1  cells  and  their  cytokines  IL-10  and  IFN-,
inhibiting  the  production  of  Th2, Th17  cells  and  their  cytokines  IL-13  and IL-17A  in  BALB/c  mice  model.
These  results  suggested  that  infant  PCV7  immunization  may  serve  as  an  effective  measure  to  preventeywords:
nfant PCV7 immunization
llergic  airway disease
oung  adulthood
h2
h17
+
young  adulthood  mice  AAD.
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. Introduction
Asthma is a common illness throughout the world which
haracterized with chronic airway inﬂammation, airway hyperre-
ponsiveness (AHR) and airway remodeling. Despite advances in
he understanding of the mechanisms of allergic asthma, current
herapies only alleviate/control the symptoms of asthma. There is
 need to look for other treatment approaches.
The recent world-wide changes in asthma prevalence imply
igniﬁcant environmental effects on asthma. Reduced exposure
o bacteria or their products is associated with increased asthma,
tilization of immunoregulatory treatments that based on bacterial
omponents may  have beneﬁts for the suppression of asthma [1].
tudies demonstrated CpG-ODNs, BCG can inhibit allergic airway
isease (AAD) in mouse models [2,3]. However, treatments with
pG-ODN may  induce harmful side effects [2], while BCG has no
∗ Corresponding author. Tel.: +86 23 63632386; fax: +86 23 63622754.
E-mail address: luozhengxiu816@163.com (Z. Luo).
ttp://dx.doi.org/10.1016/j.vaccine.2014.02.013
264-410X © 2014 The Authors. Published by Elsevier Ltd. Open access under CC BY-NC-ND efﬁcacy on allergic asthma in human trials [4]. Pneumococci is a
common respiratory pathogen, causing pneumonia, otitis media,
meningitis and septicemia. Pneumococcal vaccination is recom-
mended to prevent invasive pneumococcal infection in high-risk
groups including asthmatics [5]. Epidemiological studies demon-
strated that 7-valent pneumococcal conjugate vaccine (PCV7)
immunization reduce the incidence of asthma and associated
hospitalizations in both children and the elderly [6,7]. Thorburn
et al. [8] stated PCV7 immunization in adulthood mice inhibit
the hallmark features of AAD through promotion of Tregs and
suppression of Th2 cells production. Recent studies indicated Th17
cells play vital role in asthma pathogenesis [9–11]. Furthermore,
PCV7 immunization is currently administered in infancy to prevent
childhood pneumococci infections. Whether infant PCV7 immu-
nization can alter young adulthood CD4+T cell subsets and inhibit
AAD or not remains elusive. In this study we  investigated the effects
of infant PCV7 immunization on young adulthood AAD in mouse
models. We  demonstrated that infant PCV7 immunization attenu-
ate young adulthood mice hallmark features of AAD by promoting
Foxp3+Treg, Th1 cells and inhibiting Th2, Th17 cells production.
license.
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. Materials and methods
.1.  Mice, immunization, and treatment
BALB/c mice (6–8 weeks), free of speciﬁc pathogens, were main-
ained in individually ventilated cages, housed in autoclaved cages
nd fed on OVA-free diets, in an air-conditioned room on a 12 h
ight/dark cycle. Sterile special processing forage and water were
rovided adequately. Cages, bedding, food, and water were ster-
lized before use. Pregnant mice went into labor on 20 day of
regnancy and newborn mice were raised and maintained in the
ame conditions. Mice were divided into the following groups:
1) sensitizations and challenges with ovalbumin (OVA group); (2)
reatment with PCV7 immunization in infant, sensitizations and
hallenges with OVA in adult (PCV7 + OVA group); (3) the control
roup. On day 21, mice in the PCV7 + OVA group were admin-
stered 7-valent pneumococcal conjugate vaccine (PCV7, Wyeth,
SA) 33 l intranasally every 12 h for three doses [8]. The mice in
he OVA and PCV7 + OVA groups were sensitized intraperitoneally
ith 100 g ovalbumin (OVA, Sigma) diluted in 50% aluminum
ydroxide (Pierce) to a total volume of 200 l on day 28 and day 42.
rom day 49 to 52, the mice were challenged with OVA aerosolized
or 30 min  every day lasting for 4 days. The control group mice
ere sensitized and challenged with sterile PBS at the same time.
AD was assessed 24 h after the ﬁnal challenge. In our experiment,
ach experiment was repeated three times. Two to three mice were
sed in every experimental test described hereafter. This study was
pproved by the Institutional Animal Care and Research Advisory
ommittee at the Chongqing Medical University. All experimental
nimals were used in accordance with the guidelines issued by the
hinese Council on Animal Care.
.2. Airway hyperresponsiveness
AHR  was assessed in vivo by measuring changes in transpul-
onary resistance using a mouse plethysmograph and methods
imilar to those previously described [12]. Brieﬂy, 24 h after the
nal challenge, AHR was assessed in conscious, unrestrained mice
y means of whole-body plethysmography (Emca instrument;
llmedicus, France). Each mouse was placed into a plastic chamber
nd exposed to aerosolized PBS followed by increasing concentra-
ions of an aerosolized methacholine (Sigma-Aldrich, St. Louis, Mo.
SA) solution (3.125, 6.25, 12.5, 25, and 50 mg/ml; Sigma) in PBS for
 min  exposures and then the mice had a rest for 2 min, after which
 computer program was used to calculate Penh from the contin-
ously recorded pressure and ﬂow data for 5 min. Then take the
verage of the 5 min  records as the value of Penh of this concentra-
ion. Penh is a dimensionless value and correlates with pulmonary
irﬂow resistance. It represents a function of the ratio of peak expi-
atory ﬂow to peak inspiratory ﬂow and a function of the timing of
xpiration.
.3. Lung histopathology
After  formalin ﬁxation, the left lung was dissected and embed-
ed in parafﬁn. Sections of 4 m thickness were cut and stained
ith hematoxylin and eosin (H&E; Sigma). Tissues were sub-
equently mounted and coverslipped by use of Dako mounting
edium (Dakocytomation, Denmark, CA). The degree of airway
nﬂammatory cell inﬁltration was scored in a double-blind fashion
y two independent investigators. Lung lesions were scored semi-
uantitatively as described by other researchers [13]. The severity
f inﬂammation was evaluated by assigning a value of 0 point for
ormal; 1 point for few cells; 2 points for a ring of inﬂammatory
ells 1 cell layer deep; 3 points for a ring of inﬂammatory cells 2 (2014) 2079–2085
to  4 cells deep; 4 points for a ring of inﬂammatory cells of >4 cells
deep.
2.4. Bronchoalevolar lavage
Bronchoalveolar lavage ﬂuid (BALF) was obtained by instilling
and collecting two  aliquots of 1 ml  each of PBS through an adapter
cannula inserted through rings of the exposed trachea of eutha-
nized mice 24 h after ﬁnal challenge with OVA. BALF was pooled
to obtain one sample for each mouse. Erythrocytes were lysed,
and the remaining cells were cytocentrifuged 2500 rpm for 5 min.
Total cell numbersin the BALF were determined using a standard
hemocytometer. Differential cell counts were performed based on
standard morphological and staining characteristics of at least 250
cells per sample. Supernatant was  stored at −80 ◦C. All slides were
characterized by a single blinded examiner to eliminate bias.
2.5.  BALF cytokine measurements
Cytokine  concentrations in BALF were measured with commer-
cial enzyme-linked immunosorbent assay (ELISA) kits according to
the manufacturer’s instructions. ELISA kits used for the measure-
ment of IFN-, IL-5, and IL-10 were purchased from Sizhengbai
(Beijing, China), ELISA kits for detection of IL-4 and TGF- was  pur-
chased from Xinbosheng (Beijing, China), and the IL-17A and IL-13
detection ELISA kits were purchased from Bender.
2.6. Flow cytometric analysis of MLN CD4+T cell
The  mediastinal lymph nodes (MLN) were removed and forced
through a 70 m cell ﬁlter (BD, Bedford, MA,  USA) to obtain sin-
gle cell suspensions. Single cell suspensions in MLN  were stained
for surface-associated CD4(anti-CD4-FITC, BD Pharmingen, USA),
CD3(anti-CD3-CyTM7, BD Pharmingen, USA), CD25(anti-CD25-PE,
e Bioscience, USA), then ﬁxed, permeabilized and stained for intra-
cellular IFN-(anti-IFN--PerCP-CyTM5.5,-BD Pharmingen, USA),
IL-17A (anti-IL-17A-PE, BD Pharmingen, USA), IL-4(anti-IL-4-APC,
BD Pharmingen, USA) and Foxp3 (anti-Foxp3-PE-Cy5, e Bioscience,
USA) and analyzed by ﬂow cytometry (FACS Canto, BD Biosciences,
USA).
2.7. Statistics
Results were analyzed using GraphPad Prism (version 5.0;
GraphPad, La Jolla, CA) and expressed as mean ± s.e.m. Results were
interpreted using either one-way analysis of variance and Tukey’s
post hoc test, or two-way analysis of variance and Bonferroni’s post
hoc test. Differences were considered statistically signiﬁcant when
P < 0.05.
3. Results
3.1. Infant PCV7 immunization suppressed young adulthood
airway eosinophilic and neutrophilic inﬂammation in BALB/c mice
asthma model
OVA  sensitization and challenge induced the development
of AAD: total inﬂammatory cells, eosinophils and neutrophils
accumulation in BALF were signiﬁcantly higher compared
with controls (14.58 ± 2.50 × 105 cells/mlvs 2.34 ± 0.36 × 105
cells/ml, 14.75 ± 1.77 × 104 cells/ml vs 0.48 ± 0.15 × 104 cells/ml,
63.39 ± 9.28 × 104 cells/ml vs 9.30 ± 1.10 × 104 cells/ml, respec-
tively, P < 0.001). In contrast, the number of eosinophils and
neutrophils was  dramatically reduced in infant PCV7 immunized
group mice compared with the OVA group (2.15 ± 0.29 × 104
cells/mlvs 14.75 ± 1.77 × 104 cells/ml, 20.13 ± 3.7 × 104 cells/ml
L. Zhang et al. / Vaccine 32 (2014) 2079–2085 2081
Fig. 1. Infant PCV7 immunization inhibited OVA-induced airway eosinophilic and neutrophilic inﬂammation in a BALB/c mouse AAD model. Mice in PCV7 + OVA and OVA
group  were sensitized and challenged with OVA. 24 h after the ﬁnal challenge, BALF samples were collected and total and inﬂammatory cells were counted. (A) Total
inﬂammatory cells in BALF, (B) eosinophils in BALF, (C) neutrophils in BALF. Data were expressed as mean ± s.e.m of the number of cells in each group of mice. * P < 0.05, **
P < 0.01, *** P < 0.001 as compared with the control group. # P < 0.05, ## P < 0.01, ### P < 0.001 as compared with OVA group (n = 6–8/group).
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HE)  24 h after the ﬁnal challenge are representative of each group mice. Magniﬁca
s 63.39 ± 9.28 × 104 cells/ml, respectively, P < 0.001) (Fig. 1).
hese data demonstrated that infant PCV7 immunization
an suppress OVA-induced airway eosinophilic and neu-
rophilic inﬂammation in young adulthood BALB/c mice asthma
odel.
.2. Effects of infant PCV7 immunization on lung histopathology
uring AAD
In  control group mice, there was little tissue inﬂammation. Pul-
onary alveolar, peribronchiolar and perivascular inﬂammatory
ig. 3. After HE-stainning, lung tissue section were scored for levels of alveolitis, peri
lveolitis, perivascular, and peribronchial inﬂammation. Data are shown as mean ± s.e.m
B)  histological scores of pulmonary perivasculitis, (C) histological scores of pulmonary pe
P < 0.05, ## P < 0.01, ### P < 0.001 as compared with OVA group (n = 6–8/group).ALB/c mice. Data of mouse lung tissue sections stained with hematoxylin and eosin
 × 100 and B × 400.
inﬁltrate  of inﬂammatory cells in OVA group mice was  denser
than that in control group mice. In infant PCV7 immunized group
mice, pulmonary alveolar,peribronchiolar and perivascular cellu-
lar inﬁltration signiﬁcantly lower than that in OVA group (Fig. 2).
As shown in Fig. 3, the inﬂammation scores of pulmonary alve-
olitis, pulmonary perivasculitis and pulmonary peribronchiolitis
in infant PCV7 immunized mice were signiﬁcantly lower than
that in OVA group (3.00 ± 0.26 vs 1.17 ± 0.17, P < 0.001, 3.67 ± 0.21
vs 2.17 ± 0.31, P < 0.001, 3.33 ± 0.21 vs 1.83 ± 0.31, respectively,
P < 0.01). Thus, infant PCV7 immunization suppressed airway
inﬂammation in young adulthood asthmatic mice.
vasculitis and peribronchial inﬂammation. Infant PCV7 immunization decreased
 from three separated experiments. (A) Histological scores of pulmonary alveolitis,
ribronchiolitis. * P < 0.05, ** P < 0.01, *** P < 0.001 as compared with the control group.
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Fig. 4. Experimental mice were sensitized with OVA at 4 and 6 weeks of age, and
they were challenged with allergen for 4 days at 7 weeks of age. AHR (Penh) in
reaction to increased doses of nebulized methacholine was measured by a whole-
body plethysmograph in the experimental groups and control group after the 24 h
of the ﬁnal challenge. Data are shown as the mean ± s.e.m of Penh from experimen-
tal  and control groups of mice. * P < 0.05, ** P < 0.01, *** P < 0.001 as compared with
the  control group. # P < 0.05, ## P < 0.01, ### P < 0.001 as compared with OVA group
(n  = 6–8/group).
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However, the production of Foxp3+Treg and Th1 cells in the infant
PCV7 immunized group mice was signiﬁcantly higher than that
F
P.3. Infant PCV7 immunization inhibited young adulthood mice
HR  during AAD
AHR  was evaluated by the calculation of Penh values
enhanced pauses) 24 h after the ﬁnal challenge. OVA sensitiza-
ion and challenge resulted in increased AHR. The Penh value
or OVA group was signiﬁcantly higher than that in the con-
rol group at methacholine concentrations 6.25 mg/ml  (P < 0.01),
2.5 mg/ml  (P < 0.001), 25 mg/ml  (P < 0.001), and 50.0 mg/ml
P < 0.001). However, PCV7 + OVA group mice had signiﬁcantly
ower Penh values compared to values obtained from mice in
he OVA group from 25 to 50.0 mg/ml  (P < 0.001, respectively)
Fig. 4).
ig. 5. Infant PCV7 immunization altered CD4+T cell cytokines in a BALB/c AAD model. 
 < 0.001 as compared with the control group. # P < 0.05, ## P < 0.01, ### P < 0.001 as comp (2014) 2079–2085
3.4. Infant PCV7 immunization inhibited IL-13, IL-17A while
increased  IFN- , IL-10 cytokines production during AAD
To  investigate the effects of infant PCV7 immunization on
CD4+T cell subsets production during AAD, CD4+T cell cytokines
in BALF were analyzed. As expected, OVA sensitized and chal-
lenged mice exhibited dramatically increased IL-13, IL-17A
production (87.14 ± 7.12 pg/ml vs 40.62 ± 3.59 pg/ml, P < 0.001,
247.70 ± 35.81 pg/ml vs 158.90 ± 16.40 pg/ml, P < 0.05) and signif-
icantly decreased IFN-, IL-10 production (18.07 ± 1.13 pg/ml
vs 33.16 ± 1.87 pg/ml, P < 0.001, 122.30 ± 18.53 pg/ml vs
223.10 ± 35.92 pg/ml, P < 0.05) compared with the control group
mice. However, the production of IL-13, IL-17A in the infant
PCV7 immunized group mice were signiﬁcantly lower than that
in the OVA group mice(31.93 ± 4.36 pg/ml vs 87.14 ± 7.12 pg/ml,
P < 0.001, 120.90 ± 9.56 pg/ml vs 247.70 ± 35.81 pg/ml, P < 0.01).
IFN-, IL-10 was signiﬁcantly higher in the infant PCV7 immunized
group mice than that in the OVA group mice. (27.89 ± 1.83 pg/ml
vs 18.07 ± 1.13 pg/ml, P < 0.001, 228.50 ± 27.47 pg/ml vs
122.30 ± 18.53 pg/ml, P < 0.05). However, there was  no signiﬁ-
cant difference of IL-4, IL-5 and TGF- production between control,
PCV7 + OVA and OVA group mice (Fig. 5).
3.5. Infant PCV7 immunization promoted Foxp3+Treg, Th1 while
inhibited Th2 and Th17 cells production during AAD
To  investigate the effects of infant PCV7 immunization on CD4+T
cell subsets production during AAD, CD4+T cell subsets in MLN
were analyzed. As expected, OVA sensitized and challenged mice
exhibited dramatically decreased Foxp3+Treg, Th1 cells production
(8.66 ± 0.37% vs 10.49 ± 0.57%, P < 0.05, 2.08 ± 0.37% vs 4.87 ± 0.14%,
respectively, P < 0.001) and signiﬁcantly increased Th2, Th17 cells
production (0.75 ± 0.07% vs 0.35 ± 0.04%, P < 0.001, 2.17 ± 0.23% vs
0.93 ± 0.10%, P < 0.001) compared with the control group mice.in the OVA group mice (12.53 ± 0.28% vs 8.66 ± 0.37%, P < 0.001,
3.64 ± 0.20% vs 2.08 ± 0.37%, P < 0.001), Th2 and Th17 cells were
Cytokines of CD4+T cells in BALF were measured by ELISA. * P < 0.05, ** P < 0.01, ***
ared with OVA group (n = 6–8/group).
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Fig. 6. Infant PCV7 immunization altered CD4+T cell immune response in a BALB/c AAD model. Subsets of CD4+T cells in MNL  were measured by ﬂow cytometric. (A)
CD4+CD25+Foxp3+Treg; (B) CD4+IFN-+ T(Th1); (C) CD4+IL-4+ T(Th2); (D) CD4+IL-17+ T(Th17). The data represent mean ± s.e.m. The data (E–H), respectively, represent
p + e lymp * ** ***
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igniﬁcantly lower in the infant PCV7 immunized group mice than
hat in the OVA group mice (0.44 ± 0.04% vs 0.75 ± 0.10%, P < 0.01,
.63 ± 0.10% vs 2.17 ± 0.23%, P < 0.05) (Fig. 6A–H). These data indi-
ated that infant PCV7 immunization promoted Foxp3+Treg, Th1
hile suppressed Th2, Th17 cells production in young adulthood
ice during AAD.
.  Discussion
Epidemiological studies in humans and experimental work in
nimals suggest that PCV7 can suppress allergic airway inﬂamma-
ion [7,8]. Previous studies suggested PCV7 immunization in adult
ice inhibited hallmark features of AAD through the induction
f Tregs and suppression of Th2 cells [8]. In this investiga-
ion we have demonstrated infant PCV7 immunization suppress
oung adulthood hallmark features of AAD in mouse models. Our
tudy indicated that infant PCV7 immunization not only promote
oxp3+Treg and Th1 cells, but also inhibit Th2 and Th17 cells
roduction, which resulted in the increased secretion of IL-10, IFN-
 and decreased production of IL-13, IL-17A during AAD mouse
odel. Infant PCV7 immunization can alter adaptive immune
esponse in young adulthood life and suppress the development
f young adulthood mice allergic asthma, which suggested its
otential role as an immunoregulatory treatment to prevent young
dulthood asthma.
Sensitization and challenge with OVA induces strong polarized
h2 immune response. Th2 cells have important role in the patho-
enesis of asthma [14,15]. Th2 cells recruited into the airway causehocyte gate of MLN  in BALB/c mice. P < 0.05, P < 0.01, P < 0.001 as compared
n = 6–8/group).
mucus hypersecretion, airway remodeling, and AHR. Th2 cells asso-
ciated cytokines can initiate and accelerate allergic inﬂammation
[14,16]. IL-13 may  play a vital role in asthma pathogenesis. IL-
13 can induce airway inﬂammation, AHR, mucus secretion, and
tissue remodeling [16–18]. IL-13 can facilitate the production of
antigen speciﬁc antibodies [19] and mucous cells in the bronchial
epithelium [20]. In this study, we  demonstrated that infant PCV7
immunization could alter young adulthood mice adaptive immune
response to OVA antigen, and that resulted in the suppression of
Th2 cells, IL-13 production and eosinophilia recruitment. There was
no difference of IL-4 and IL-5 production between control and OVA
group mice, which may  be associated with the increased Th17 cells
inhibiting the production IL-4 and IL-5 [21,22].
Th17 is a pro-inﬂammatory CD4+T effector cell population that
is different from Th1 and Th2 [23,24]. Th17 cells and related
cytokines play pivotal role in the pathogenesis of allergic asthma
[25,26]. Th17 responses in chronic allergic airway inﬂammation
abrogate regulatory T-cell-mediated tolerance and contribute to
airway remodeling [27]. Antigen speciﬁc Th17 cells can promote
Th2-cell-mediated eosinophil recruit into the airways [9]. Allergen
driven Th17 cells resulted in asthma exacerbations or accelerated
tissue damage. Studies indicated that enhanced IL-17A levels cor-
relate with increased AHR in asthmatics and allergic asthma mice
[28,29]. IL-17A can also induce human bronchial epithelial cells to
produce mucus proteins acting in concert with IL-6 [30]. IL-17A can
induce lung structural cells to secrete pro-inﬂammatory cytokines
and neutrophil chemotactic proteins, thereby inducing neutrophil
inﬁltration [29,31,32]. Furthermore, IL-17A can mediate allergic
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eactions by enhancing IgE class-switch recombination in B cells.
26,33] Here we demonstrated that infant PCV7 immunization may
orrect the imbalance of Th17 cells, inhibit harmful effect of Th17
nd IL-17A, thus inhibit AAD in mouse model.
Foxp3+Treg cell is a distinct subset of CD4+T cells which can sup-
ress effector CD4+T cells responses [34,35]. Studies showed that
oxp3+Treg cells play a crucial role in allergic diseases including
sthma [36–39]. Foxp3+Treg cells can suppress Th2 and Th17 cells
ediated inﬂammation and prevent airway inﬂammation, AHR
oth in asthmatic patients and in animal experiments [39,40]. The
unctions of Foxp3+Treg cells are impaired in asthma [41,42]. We
howed here that infant PCV7 immunization can promote the pro-
uction of Foxp3+Treg cells and inhibit Th2, Th17 cells and their
ytokines IL-13, IL-17A, which resulted in relieving the manifesta-
ions of AAD.
A  recent study showed respiratory streptococcus pneumoniae
nfection suppresses hallmark features of AAD and has potential
eneﬁts for asthma. Streptococcus pneumoniae infection sup-
resses allergic airways disease by inducing regulatory T-cells
43]. In this study, we demonstrated infant PCV7 immunization
uppress young adulthood hallmark features of AAD in mouse mod-
ls. Whether there are any key immunoregulatory components in
treptococcus pneumoniae which can inhibit hallmark features of
AD needs further investigation.
But there were some limitations in this study. First, as previ-
us study [8] have demonstrated intramuscular administration of
CV7 had limited effects on AAD, we did not design a study to
nvestigate the effect of infant PCV7 immunization intramuscu-
arly on young adulthood CD4+T cell subsets. Second, we  did not
nvestigate the mechanism of infant PCV7 immunization increased
oxp3+Treg cells in AAD mouse model. Literatures showed imma-
ure DC can promote the production of Foxp3+Treg cells [44–46],
hether infant PCV7 immunization can alter the maturation of DC
r not remains unclear, which is the work we will do hereafter.
In  conclusion, infant PCV7 immunization may be an effective
easure to prevent young adulthood asthma through promoting
oxp3+Treg and Th1 cells, and inhibiting Th2 and Th17 cells.
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